{
  "hlvx": [
    "the initiation, type, number, scope, results, costs and timing of, our planned clinical trials of HIL-214 and preclinical studies or clinical trials of other potential vaccine candidates we may choose to pursue in the future, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;",
    "the costs and timing of manufacturing for HIL-214, or any future vaccine candidates, and placebo to be used in our trials, as well as commercial scale manufacturing, if any vaccine candidate is approved;",
    "the costs, timing and outcome of regulatory meetings and reviews of HIL-214 or any future vaccine candidates;",
    "any delays and cost increases that may result from the COVID-19 pandemic;",
    "the costs of obtaining, maintaining, enforcing and protecting our patents and other intellectual property and proprietary rights;",
    "our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls over financial reporting;",
    "the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development and commercial personnel;",
    "the terms and timing of establishing and maintaining collaborations, license agreements and other similar arrangements;",
    "the timing and amount of the milestone, royalty or other payments we must make to Takeda and any future licensors;",
    "the costs and timing of establishing or securing sales and marketing capabilities if HIL-214 or future vaccine candidates are approved;",
    "our ability to receive recommendations from the ACIP, or other foreign national immunization technical advisory groups (NITAGs), and achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;",
    "vaccine recipients’ willingness to pay out-of-pocket for any approved products in the absence of coverage and/or adequate reimbursement from third-party payors; and",
    "costs associated with any products or technologies that we may in-license or acquire."
  ],
  "blco": [
    "further material closures or disruptions to our manufacturing sites (including Milan, Italy and our two sites in China);",
    "lack of availability of active pharmaceutical ingredients, or APIs, and intermediates, or other supply chain disruptions, including for some of our key products;",
    "continued alternative working arrangements, including personnel working remotely and additional cleaning or sterilization protocols at our production facilities, which could negatively impact our business should such arrangements remain for an extended period of time;",
    "interruption or delays in the operations of the United States Food and Drug Administration (“FDA”), the European Medical Agency (“EMA”) and other regulatory authorities, which may impact review and approval timelines for our planned trials and launches;",
    "delays or difficulties in enrolling patients in our clinical trials;",
    "delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff;",
    "diversion of health care resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials;",
    "interruption or postponement of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical study endpoints;",
    "limitations on employee resources that would otherwise be focused on our business and operations, such as the conduct of our preclinical studies and clinical trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people;",
    "delays in or postponements of our clinical trial programs as a result of “stay at home” orders affecting our research facilities or the closure of such research facilities, which may impact the timing, approval and launch of the affected clinical trial programs;",
    "recurrence of deferrals of elective or elective medical procedures and of doctor visits, and reduced use of contact lens, as consumers may fear that eye contact could result in infection spread, which may reduce demand for certain of the Company’s products, including our contact lens products and certain branded pharmaceutical products in our eye care businesses;",
    "delays or difficulties in our and our business partners’ ability to access physicians, which may in turn impact our ability to train physicians to use our devices and provide needed services; and",
    "adverse effects on the regional economies in which we operate which could reduce demand for certain of the Company’s products."
  ],
  "aust": [
    "had a public float of less than $250 million as of the last business day of its most recently completed second fiscal quarter, computed by multiplying the aggregate worldwide number of shares of its voting and non-voting common equity held by non-affiliates by the price at which the common equity was last sold, or the average of the bid and asked prices of common equity, in the principal market for the common equity; or",
    "in the case of an initial registration statement under the Securities Act, or the Exchange Act of 1934, as amended, which we refer to as the Exchange Act, for shares of its common equity, had a public float of less than $250 million as of a date within 30 days of the date of the filing of the registration statement, computed by multiplying the aggregate worldwide number of such shares held by non-affiliates before the registration plus, in the case of a Securities Act registration statement, the number of such shares included in the registration statement by the estimated initial public offering price of the shares; or",
    "in the case of an issuer whose public float as calculated under the previous two bullet points was zero or less than $700 million, had annual revenues of less than $100 million during the most recently completed fiscal year for which audited financial statements are available."
  ],
  "ee": [
    "at the end of a specified time period following certain events of force majeure or the outbreak of war;",
    "extended unexcused service interruptions or deficiencies;",
    "loss of or requisition of the FSRU;",
    "the occurrence of an insolvency event; and",
    "the occurrence of certain uncured, material breaches."
  ],
  "nke": [
    "Our sales are impacted by discretionary spending by consumers. Declines in consumer spending have in the past and in the future may result in reduced demand for our products, increased inventories, reduced orders from retailers for our products, order cancellations, lower revenues, higher discounts and lower gross margins.",
    "In the future, we may be unable to access financing in the credit and capital markets at reasonable rates in the event we find it desirable to do so.",
    "We conduct transactions in various currencies, which creates exposure to fluctuations in foreign currency exchange rates relative to the U.S. Dollar. Continued volatility in the markets and exchange rates for foreign currencies and contracts in foreign currencies could have a significant impact on our reported operating results and financial condition.",
    "Continued volatility in the availability and prices for commodities and raw materials we use in our products and in our supply chain (such as cotton or petroleum derivatives) could have a material adverse effect on our costs, gross margins and profitability. In addition, supply chain issues caused by factors including the COVID-19 pandemic and geopolitical conflicts have impacted and may continue to impact the availability, pricing and timing for obtaining commodities and raw materials.",
    "If retailers of our products experience declining revenues or experience difficulty obtaining financing in the capital and credit markets to purchase our products, this could result in reduced orders for our products, order cancellations, late retailer payments, extended payment terms, higher accounts receivable, reduced cash flows, greater expense associated with collection efforts and increased bad debt expense.",
    "If retailers of our products experience severe financial difficulty, some may become insolvent and cease business operations, which could negatively impact the sale of our products to consumers. If contract manufacturers of our products or other participants in our supply chain experience difficulty obtaining financing in the capital and credit markets to purchase raw materials or to finance capital equipment and other general working capital needs, it may result in delays or non-delivery of shipments of our products."
  ],
  "pepg": [
    "complete preclinical activities for our programs in DMD and DM1 and advance them into and through clinical development;",
    "advance any additional product candidates we identify through our research programs into IND- or CTA-enabling studies and clinical trials following regulatory clearance to commence clinical research;",
    "continue to develop and expand the capabilities of our proprietary EDO platform;",
    "seek marketing approvals for any product candidates that successfully complete clinical trials;",
    "obtain, expand, maintain, defend and enforce our intellectual property portfolio;",
    "hire additional clinical, regulatory and scientific personnel;",
    "establish manufacturing sources for our product candidates and secure supply chain capacity to provide sufficient quantities for preclinical and clinical development and commercial supply;",
    "ultimately establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain marketing approval; and",
    "add operational, legal, compliance, financial and management information systems and personnel to support our research, product development and future commercialization efforts, as well as to support our operations as a public company."
  ],
  "v": [
    "third party disruptions, including potential outages at network providers, call centers and other suppliers;",
    "increased consumer dispute volumes due to travel or event cancellations and the speed or accuracy in processing refunds;",
    "increased cyber and payment fraud risk, as cybercriminals attempt DDoS related attacks, phishing scams and other disruptive actions, given the shift to online banking, ecommerce and other online activity, as well as more employees working remotely as a result of the ongoing pandemic;",
    "challenges to the availability and reliability of our network due to changes to normal operations, including the possibility of one or more clusters of COVID-19 cases occurring at our data centers, affecting our employees, or affecting the systems or employees of our issuers, acquirers or merchants;",
    "additional regulatory requirements, including, for example, government initiatives or requests to reduce or eliminate payments fees or other costs. A number of countries have taken steps to temporarily cap interchange or other fees on electronic payments as part of their COVID-19 economic relief measures. It is possible that some or all of these caps may become permanent over time, or that we see governments introduce additional and/or new pricing caps in future economic relief initiatives. In addition, proponents of interchange and/or MDR regulation may try to position government intervention as necessary to support recovery efforts. In an overall soft global economy, such pricing measures could result in additional financial pressures on our business; and",
    "workforce impacts, such as difficulty recruiting, retaining, training, motivating and developing employees due to evolving health and safety protocols; changing worker expectations and talent marketplace variability regarding flexible work models; restrictions on immigration, travel and employee mobility; and the challenges of maintaining our strong corporate culture, which values communication, collaboration and connections, while some employees continue to work from home."
  ],
  "cl": [
    "changing macroeconomic conditions in our markets, including as a result of inflation, the war in Ukraine, volatile commodity prices and increases in the cost of raw and packaging materials, labor, energy and logistics;",
    "political or economic instability, geopolitical events, such as the war in Ukraine, environmental events, widespread health emergencies, such as COVID-19 or other pandemics or epidemics, natural disasters or social or labor unrest;",
    "changes in exchange rates for foreign currencies, which may reduce the U.S. dollar value of revenues, profits and cash flows from non-U.S. markets or increase our supply costs, as measured in U.S. dollars, in those markets;",
    "exchange controls and other limits on our ability to import or export raw materials or finished product, including as a result of COVID-19 and the war in Ukraine, or to repatriate earnings from overseas;",
    "lack of well-established, reliable and/or impartial legal systems in certain countries where we operate and difficulties in enforcing contractual, intellectual property or other legal rights;",
    "foreign ownership and investment restrictions and the potential for nationalization or expropriation of property or other resources; and",
    "changes to trade policies and agreements and other foreign or domestic legal and regulatory requirements, including those resulting in potentially adverse tax consequences or the imposition of and/or the increase in onerous trade restrictions and/or tariffs, sanctions, price controls, labor laws, travel or immigration restrictions (including as a result of COVID-19 or other pandemics or epidemics), profit controls or other government controls, including as a result of the war in Ukraine."
  ],
  "bc": [
    "the risk that the businesses of Brunswick and Navico will not be integrated successfully;",
    "disruption from the proposed transaction could make it more difficult to maintain business and operational relationships;",
    "the possibility that the expected synergies and value creation from the proposed transaction will not be realized or will not be realized within the expected time period; and",
    "the risk that unexpected costs will be incurred."
  ],
  "cri": [
    "the failure of the computer systems, including those of third-party vendors, that operate our eCommerce sites and mobile applications, including, among others, inadequate system capacity, service outages, computer viruses, human error, changes in programming, security breaches, system upgrades or migration of these services to new systems;",
    "disruptions in telecommunications services or power outages;",
    "reliance on third parties for computer hardware and software, as well as delivery of merchandise to our customers on-time and without damage;",
    "limitations of shipping volumes which may be imposed by service providers;",
    "rapid technology changes;",
    "the failure to deliver products to customers on-time and within customers’ expectations;",
    "credit or debit card, or other electronic payment-type, fraud, or disruptions in payment systems;",
    "the diversion of sales from our physical stores;",
    "natural disasters or adverse weather conditions;",
    "changes in applicable federal, state and international regulations;",
    "liability for online content; and",
    "consumer privacy concerns and regulation."
  ],
  "asns": [
    "our ability to obtain additional debt or equity financing for working capital, capital expenditures, debt service requirements, acquisitions and general corporate or other purposes may be limited;",
    "a portion of our cash flows from operations will be dedicated to the payment of principal and interest on the indebtedness and will not be available for other purposes, including operations, capital expenditures and future business opportunities;",
    "our ability to adjust to changing market conditions may be limited and may place us at a competitive disadvantage compared to less-leveraged competitors, if such exist; and",
    "we may be vulnerable during a downturn in general economic conditions or in our business, or may be unable to carry on capital spending that is important to our growth."
  ],
  "apld": [
    "continued worldwide growth in the adoption and use of Ether and Bitcoin as mediums of exchange;",
    "governmental and quasi-governmental regulation of Ether and Bitcoin and its use, or restrictions on or regulation of access to and operation of the Ethereum and Bitcoin networks or similar cryptoasset systems;",
    "changes in consumer demographics and public tastes and preferences;",
    "the maintenance and development of the open-source software protocol of the network, including software updates and changes to network protocols that could introduce bugs or security risks;",
    "the increased consolidation of contributors to the Ethereum and Bitcoin blockchains through mining pools;",
    "the availability and popularity of other forms or methods of buying and selling goods and services, including new means of using fiat currencies;",
    "the use of the networks supporting cryptoassets for developing smart contracts and distributed applications;",
    "general economic conditions and the regulatory environment relating to cryptoassets; and",
    "negative consumer sentiment and perception of Ethereum and Bitcoin specifically and cryptoassets generally."
  ],
  "mmm": [
    "The Company’s results are impacted by the effects of, and changes in, worldwide economic, political, regulatory, international trade and other external conditions."
  ],
  "ehc": [
    "licensure, certification, enrollments, and accreditation;",
    "policies, either at the national or local level, delineating what conditions must be met to qualify for reimbursement under Medicare (also referred to as coverage requirements);",
    "coding and billing for services;",
    "requirements of the 60% compliance threshold under the 2007 Medicare Act;",
    "relationships with physicians and other referral sources, including physician self-referral and anti-kickback laws;",
    "quality of medical care;",
    "use and maintenance of medical supplies and equipment;",
    "maintenance and security of patient information and medical records;",
    "minimum staffing;",
    "acquisition and dispensing of pharmaceuticals and controlled substances; and",
    "disposal of medical and hazardous waste."
  ],
  "dis": [
    "Our programming and production operations compete to obtain creative, performing and business talent, sports and other programming, story properties, advertiser support and market share with other studio operators, television networks, SVOD providers and other new sources of broadband delivered content.",
    "Our television networks and stations and DTC offerings compete for the sale of advertising time with other television and SVOD services, as well as with newspapers, magazines, billboards and radio stations. In addition, we increasingly face competition for advertising sales from internet and mobile delivered content, which offer advertising delivery technologies that are more targeted than can be achieved through traditional means.",
    "Our television networks compete for carriage of their programming with other programming providers.",
    "Our theme parks and resorts compete for guests with all other forms of entertainment, lodging, tourism and recreation activities.",
    "Our content sales/licensing operations compete for customers with all other forms of entertainment.",
    "Our consumer products business competes with other licensors and creators of IP.",
    "Our DTC businesses compete for customers with an increasing number of competitors’ DTC offerings, all other forms of media and all other forms of entertainment, as well as for technology, creative, performing and business talent and for content."
  ],
  "wetg": [
    "have an auditor report regarding our internal controls of financial reporting pursuant to Section 4(b) of the Sarbanes-Oxley Act;",
    "present more than two years audited financial statement in our registration statement and annual reports on Form 10-K and present selected financial data in such registration statements and annual reports;",
    "Make risk factor disclosure in our annual reports of Form 10-K; and",
    "Make certain otherwise required disclosures in our annual reports on Form 10-K and quarterly reports on Form 10-Q."
  ],
  "bj": [
    "our failure to remain competitive in our pricing relative to our competitors;",
    "our failure to provide the expected quality of merchandise;",
    "our failure to offer the mix of products that our members want;",
    "events that harm our reputation or the reputation of our private brands;",
    "our failure to provide the convenience that our members may expect over time, including with respect to technology, delivery and physical location;",
    "increases to our membership fees; and",
    "increased competition from stores, clubs or internet retailers that have a more attractive mix of price, quality and convenience."
  ]
}
